Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Receivables - Other: 2020-2023

Historic Receivables - Other for Relay Therapeutics (RLAY) over the last 2 years, with Mar 2023 value amounting to $4.9 million.

  • Relay Therapeutics' Receivables - Other rose 5.21% to $4.9 million in Q1 2023 from the same period last year, while for Mar 2023 it was $4.9 million, marking a year-over-year increase of 5.21%. This contributed to the annual value of $4.9 million for FY2022, which is 8.29% up from last year.
  • According to the latest figures from Q1 2023, Relay Therapeutics' Receivables - Other is $4.9 million, which was up 0.65% from $4.9 million recorded in Q4 2022.
  • Relay Therapeutics' 5-year Receivables - Other high stood at $8.6 million for Q1 2021, and its period low was $4.2 million during Q2 2021.
  • Moreover, its 3-year median value for Receivables - Other was $4.8 million (2022), whereas its average is $5.1 million.
  • The largest annual percentage gain for Relay Therapeutics' Receivables - Other in the last 5 years was 15.27% (2022), contrasted with its biggest fall of 45.39% (2022).
  • Quarterly analysis of 4 years shows Relay Therapeutics' Receivables - Other stood at $7.7 million in 2020, then tumbled by 40.72% to $4.5 million in 2021, then increased by 8.29% to $4.9 million in 2022, then climbed by 5.21% to $4.9 million in 2023.
  • Its Receivables - Other was $4.9 million in Q1 2023, compared to $4.9 million in Q4 2022 and $4.9 million in Q3 2022.